Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: Studies with mitochondrial DNA-less ρ 0 cells and cybrids carrying MELAS mitochondrial DNA mutation

Nuclear Medicine and Biology

Volumn 39, Issue 2, 2012, Pages 177-185

  Yoshii, Yukie ^a,b   Yoneda, Makoto ^b   Ikawa, Masamichi ^b   Furukawa, Takako ^a,b   Kiyono, Yasushi ^b   Mori, Tetsuya ^b   Yoshii, Hiroshi ^a   Oyama, Nobuyuki ^b   Okazawa, Hidehiko ^b   Saga, Tsuneo ^a   Fujibayashi, Yasuhisa ^a,b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

0 cell; Cu ATSM; MELAS; Mitochondrial dysfunction; Overreduced state; PET

Indexed keywords

COPPER; COPPER 62; COPPER 64; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 60; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 62; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; INDICATOR; MITOCHONDRIAL DNA; RADIOPHARMACEUTICAL AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL STRAIN MITOCHONDRIAL DNA LESS P0 CELL; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CONTROLLED STUDY; CYBRID; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ACCUMULATION; DRUG STRUCTURE; DRUG UPTAKE; GENE MUTATION; HUMAN; HUMAN CELL; HYPOXIA; ISOTOPE LABELING; MELAS SYNDROME; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRION; OSTEOSARCOMA CELL; OVERREDUCED INTRACELLULAR STATE; OXYGEN SUPPLY; POSITRON EMISSION TOMOGRAPHY;

CELL HYPOXIA; CELL LINE, TUMOR; COPPER RADIOISOTOPES; DNA, MITOCHONDRIAL; HUMANS; MELAS SYNDROME; MITOCHONDRIA; ORGANOMETALLIC COMPOUNDS; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; THIOSEMICARBAZONES;

EID: 84856333052     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.08.008     Document Type: Article

References (48)

1. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006, 38:515-517.
2. Kobayashi Y., Momoi M.Y., Tominaga K., Momoi T., Nihei K., Yanagisawa M., et al. A point mutation in the mitochondrial tRNA(Leu)(UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes). Biochem Biophys Res Commun 1990, 173:816-822.
3. Lezza A.M., Mecocci P., Cormio A., Beal M.F., Cherubini A., Cantatore P., et al. Mitochondrial DNA 4977 bp deletion and OH8dG levels correlate in the brain of aged subjects but not Alzheimer's disease patients. FASEB J 1999, 13:1083-1088.
4. Mawrin C., Kirches E., Krause G., Schneider-Stock R., Bogerts B., Vorwerk C.K., et al. Region-specific analysis of mitochondrial DNA deletions in neurodegenerative disorders in humans. Neurosci Lett 2004, 357:111-114.
5. Goto Y., Nonaka I., Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990, 348:651-653.
6. Fukuyama R., Nakayama A., Nakase T., Toba H., Mukainaka T., Sakaguchi H., et al. A newly established neuronal rho-0 cell line highly susceptible to oxidative stress accumulates iron and other metals. Relevance to the origin of metal ion deposits in brains with neurodegenerative disorders. J Biol Chem 2002, 277:41455-41462.
7. Bandy B., Davison A.J. Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging?. Free Radic Biol Med 1990, 8:523-539.
8. Indo H.P., Davidson M., Yen H.C., Suenaga S., Tomita K., Nishii T., et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 2007, 7:106-118.
9. Pavlakis S.G., Phillips P.C., DiMauro S., De Vivo D.C., Rowland L.P. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 1984, 16:481-488.
10. King M.P., Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989, 246:500-503.
11. Yoneda M., Chomyn A., Martinuzzi A., Hurko O., Attardi G. Marked replicative advantage of human mtDNA carrying a point mutation that causes the MELAS encephalomyopathy. Proc Natl Acad Sci USA 1992, 89:11164-11168.
12. Chomyn A., Martinuzzi A., Yoneda M., Daga A., Hurko O., Johns D., et al. MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc Natl Acad Sci U S A 1992, 89:4221-4225.
13. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997, 38:1155-1160.
14. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999, 40:177-183.
15. 4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001, 42:655-661.
16. 64Cu using a 12 MeV cyclotron. Nucl Med Biol 2003, 30:535-539.
17. 64Cu-ATSM: a comparison study with FDG. Nucl Med Biol 2003, 30:529-534.
18. Oh M., Tanaka T., Kobayashi M., Furukawa T., Mori T., Kudo T., et al. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl Med Biol 2009, 36:419-426.
19. 4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 2000, 14:323-328.
20. Tanaka T., Furukawa T., Fujieda S., Kasamatsu S., Yonekura Y., Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol 2006, 33:743-750.
21. + highly tumorigenic cells and metastatic ability of mouse colon carcinoma. Nucl Med Biol 2011, 38:151-157.
22. + highly tumorigenic cells in mouse colon carcinoma. Nucl Med Biol 2010, 37:395-404.
23. 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys 2003, 55:1233-1238.
24. 4-methylthiosemicarbazone). J Nucl Med 2008, 49:201-205.
25. 60Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol 2007, 9:278-283.
26. 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008, 51:1641-1648.
27. 18F-FDG in lung cancer. J Nucl Med 2009, 50:1948-1953.
28. 4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001, 15:499-504.
29. Ikawa M., Okazawa H., Arakawa K., Kudo T., Kimura H., Fujibayashi Y., et al. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion 2009, 9:144-148.
30. 64Cu using a biomedical cyclotron. Nucl Med Biol 1997, 24:35-43.
31. Watabe M., Nakaki T., Mitochondrial complex I. inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells. Mol Pharmacol 2008, 74:933-940.
32. Dearling J.L., Lewis J.S., Mullen G.E., Welch M.J., Blower P.J. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 2002, 7:249-259.
33. Dearling J.L., Packard A.B. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol 2010, 37:237-243.
34. Moreno S.N., Mason R.P., Muniz R.P., Cruz F.S., Docampo R. Generation of free radicals from metronidazole and other nitroimidazoles by Tritrichomonas foetus. J Biol Chem 1983, 258:4051-4054.
35. Arteel G.E., Thurman R.G., Raleigh J.A. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. FEBS Lett 1998, 253:743-750.
36. Arteel G.E., Thurman R.G., Yates J.M., Raleigh J.A. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 1995, 72:889-895.
37. Rosenberger C., Rosen S., Paliege A., Heyman S.N. Pimonidazole adduct immunohistochemistry in the rat kidney: detection of tissue hypoxia. Methods Mol Biol 2009, 466:161-174.
38. Greco O., Marples B., Joiner M.C., Scott S.D. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 2003, 197:312-325.
39. Grigoryan R., Keshelava N., Anderson C., Reynolds C.P. In vitro testing of chemosensitivity in physiological hypoxia. Methods Mol Med 2005, 110:87-100.
40. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276.
41. 18F]fluoromisonidazole positron emission tomography. Int J Oncol 2007, 30:873-881.
42. 64Cu-ATSM in a rodent model of cancer. Nucl Med Biol 2008, 35:713-720.
43. 4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005, 61:1493-1502.
44. Obi-Tabot E.T., Hanrahan L.M., Cachecho R., Beer E.R., Hopkins S.R., Chan J.C., et al. Changes in hepatocyte NADH fluorescence during prolonged hypoxia. J Surg Res 1993, 55:575-580.
45. Xia C., Meng Q., Liu L.Z., Rojanasakul Y., Wang X.R., Jiang B.H. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007, 67:10823-10830.
46. Guo S., Miyake M., Liu K.J., Shi H. Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment. J Neurochem 2009, 108:1309-1321.
47. Gao L., Mejias R., Echevarria M., Lopez-Barneo J. Induction of the glucose-6-phosphate dehydrogenase gene expression by chronic hypoxia in PC12 cells. FEBS Lett 2004, 569:256-260.
48. Kletzien R.F., Harris P.K., Foellmi L.A. Glucose-6-phosphate dehydrogenase: a "housekeeping" enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress. FASEB J 1994, 8:174-181.